Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Moleculin Biotech ( (MBRX) ) has provided an update.
Moleculin Biotech, Inc. is set to host an engaging Virtual Acute Myeloid Leukemia KOL event on October 14, 2024, which will feature discussions with top medical experts on the potential of Annamycin to revolutionize AML treatment. The company also highlights their pivotal Phase 3 MIRACLE trial aimed at accelerated approval of Annamycin in combination with cytarabine for patients with relapsed or refractory AML. Investors and interested parties can join the event via webcast to gain insights into Moleculin’s advanced pipeline targeting challenging tumors and viruses.
See more insights into MBRX stock on TipRanks’ Stock Analysis page.
